Stay updated on VRDN 001 Safety and Efficacy in TED Clinical Trial
Sign up to get notified when there's something new on the VRDN 001 Safety and Efficacy in TED Clinical Trial page.

Latest updates to the VRDN 001 Safety and Efficacy in TED Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed information about the investigational drug veligrotug (VRDN-001) and its clinical trial phases, while adding a new revision number and the term 'Thyroid Eye Disease'.SummaryDifference25%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
Stay in the know with updates to VRDN 001 Safety and Efficacy in TED Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VRDN 001 Safety and Efficacy in TED Clinical Trial page.